STRO Stock Forecast & Price Target

Sutro Biopharma is supported by a compelling combination of early clinical validation, platform breadth, and a strengthened balance sheet. STRO-004 has shown confirmed and ongoing unconfirmed partial responses across PDAC, HNSCC, and NSCLC in 49 heavily pre-treated patients, while also exhibiting a cleaner safety profile than historical TF ADCs, with low discontinuation, no neuropathy or ILD/pneumonitis signal, and dose optimization now centered at 4–5 mg/kg. Financially, cash, cash equivalents, and marketable securities of $164.3MM, plus a collaboration-driven revenue base and narrowing net loss in 1Q26, support execution into at least 2Q28 and fund multiple near-term catalysts across STRO-006, STRO-227, and partnered programs.

Sutro Biopharma is a high-risk clinical-stage biotech whose valuation still depends on unproven efficacy across current and future trials, while regulatory, commercial, and partner-execution risks remain material. Although STRO-004’s early safety appears differentiated, the company’s 2Q26 financials were weak relative to expectations, with $9.8MM of revenue, $31.7MM of R&D expense, and $164.3MM in cash, underscoring continued cash burn and possible future dilution. Competition also looks increasingly challenging, as Evopoint’s TF-targeted ADC showed a 47% ORR but a clearly worse safety profile, and Sutro’s near-term outlook remains vulnerable to any disappointing data from its lead ADC programs.